Long-term efficacy and safety of Canakinumab in active Hyper-IgD syndrome (HIDS): results from an open-label study. Issue 1 (December 2015) - Aróstegui, JI; Anton, J; Calvo, I; Robles, A; Speziale, A; Joubert, Y; Junge, G; Yagüe, J